VTYX RSI Chart
Last 7 days
-12.3%
Last 30 days
-10.2%
Last 90 days
80.4%
Trailing 12 Months
-88.2%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 12, 2024 | nsv partners iii lp | sold | - | - | -695,339 | - |
Apr 12, 2024 | subramaniam somu | sold | - | - | -695,339 | - |
Apr 02, 2024 | nuss john | sold | -8,921 | 5.4034 | -1,651 | chief scientific officer |
Apr 02, 2024 | auster martin | sold | -7,591 | 5.4035 | -1,405 | chief financial officer |
Apr 02, 2024 | krueger christopher w | sold | -8,921 | 5.4036 | -1,651 | chief business officer |
Apr 02, 2024 | mohan raju | sold | -23,299 | 5.4034 | -4,312 | ceo and president |
Mar 28, 2024 | mohan raju | acquired | - | - | 11,843 | ceo and president |
Mar 28, 2024 | auster martin | acquired | - | - | 4,531 | chief financial officer |
Mar 28, 2024 | krueger christopher w | acquired | - | - | 4,531 | chief business officer |
Mar 28, 2024 | nuss john | acquired | - | - | 4,531 | chief scientific officer |
Which funds bought or sold VTYX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 10, 2024 | BROWN BROTHERS HARRIMAN & CO | new | - | 15,648 | 15,648 | -% |
May 10, 2024 | Covestor Ltd | added | 225 | - | - | -% |
May 10, 2024 | CREDIT SUISSE AG/ | sold off | -100 | -108,478 | - | -% |
May 10, 2024 | VANGUARD GROUP INC | reduced | -0.97 | 11,137,500 | 20,380,100 | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | added | 22.67 | 52,300 | 82,506 | -% |
May 10, 2024 | OSAIC HOLDINGS, INC. | sold off | -100 | -829 | - | -% |
May 10, 2024 | PNC Financial Services Group, Inc. | added | 400 | 126 | 138 | -% |
May 10, 2024 | BlackRock Inc. | reduced | -1.77 | 11,187,100 | 20,609,000 | -% |
May 10, 2024 | DIMENSIONAL FUND ADVISORS LP | reduced | -29.45 | 23,867 | 66,056 | -% |
May 10, 2024 | GROUP ONE TRADING, L.P. | reduced | -80.38 | -449,160 | 348,524 | -% |
Unveiling Ventyx Biosciences, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Ventyx Biosciences, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 48.2B | 6.8B | -8.07 | 7.03 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 19.0B | 2.0B | -57.12 | 9.47 | ||||
BMRN | 15.3B | 2.5B | 74.39 | 6.18 | ||||
INCY | 12.9B | 3.8B | 17.35 | 3.43 | ||||
MID-CAP | ||||||||
BBIO | 5.3B | 107.9M | -9.76 | 48.09 | ||||
APLS | 5.2B | 524.1M | -12.51 | 9.96 | ||||
AXSM | 3.6B | 251.0M | -12.12 | 14.31 | ||||
ARWR | 2.7B | 240.7M | -5.82 | 12.77 | ||||
ACAD | 2.5B | 813.8M | -1.5K | 3.08 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.44 | 4.66 | ||||
NVAX | 1.8B | 996.6M | -4.62 | 1.85 | ||||
CRBP | 458.7M | 881.7K | -13.59 | 481.06 | ||||
INO | 294.6M | 4.9M | -2.36 | 60.54 | ||||
IBIO | 15.6M | 2.1M | -0.67 | 7.61 |
Ventyx Biosciences, Inc. News
Balance Sheet | |||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2020Q4 |
Assets | 19.6% | 332 | 278 | 322 | 349 | 389 | 371 | 420 | 262 | 278 | 291 | 149 | - |
Current Assets | 21.0% | 320 | 264 | 308 | 347 | 387 | 331 | 418 | 252 | 258 | 263 | 146 | 0.00 |
Cash Equivalents | 175.1% | 142 | 52.00 | 57.00 | 52.00 | 64.00 | 65.00 | 263 | 45.00 | 42.00 | 71.00 | 69.00 | 0.00 |
Net PPE | 8.7% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
Liabilities | -25.7% | 25.00 | 34.00 | 38.00 | 21.00 | 18.00 | 18.00 | 37.00 | 19.00 | 19.00 | 12.00 | 12.00 | 31.00 |
Current Liabilities | -34.7% | 15.00 | 22.00 | 26.00 | 20.00 | 17.00 | 16.00 | 36.00 | 18.00 | 18.00 | 12.00 | 12.00 | 1.00 |
Shareholder's Equity | 25.9% | 307 | 244 | 284 | 328 | 372 | 354 | 384 | 243 | 259 | 279 | - | - |
Retained Earnings | -9.2% | -457 | -419 | -372 | -318 | -265 | -226 | -191 | -160 | -140 | -117 | -100 | -32.50 |
Additional Paid-In Capital | 15.3% | 765 | 663 | 657 | 647 | 637 | 581 | 576 | 405 | 401 | 397 | 12.00 | 2.00 |
Shares Outstanding | 19.0% | 70.00 | 59.00 | 59.00 | 59.00 | 58.00 | 57.00 | 52.00 | 51.00 | 51.00 | 50.00 | 3.00 | 2.00 |
Float | - | - | - | - | 1,300 | - | - | - | 385 | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 |
Cashflow From Operations | 7.8% | -47,625 | -51,655 | -34,664 | -49,282 | -30,921 | -47,264 | -23,989 | -14,792 | -12,726 | -14,687 | -11,041 | -9,903 | -3,019 | - | - |
Share Based Compensation | 6.5% | 6,543 | 6,145 | 8,008 | 7,868 | 6,567 | 4,828 | 4,167 | 4,131 | 3,444 | 1,393 | 969 | 288 | 80.00 | - | - |
Cashflow From Investing | -9.5% | 41,765 | 46,125 | 38,891 | 34,819 | -18,895 | -140,840 | 64,162 | 18,250 | -16,503 | -143,090 | -73,163 | -11.00 | 1,899 | - | - |
Cashflow From Financing | 16341.7% | 96,184 | 585 | 1,625 | 2,473 | 48,646 | -10,355 | 177,792 | 249 | 86.00 | 159,582 | 50,379 | 56,725 | 56,865 | - | - |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses: | ||
Research and development (includes related party amounts of $1,023 and $883, respectively) | $ 175,767 | $ 87,738 |
General and administrative | 32,227 | 25,398 |
Total operating expenses | 207,994 | 113,136 |
Loss from operations | (207,994) | (113,136) |
Other (income) expense: | ||
Interest income | (15,074) | (4,669) |
Other (income) expense | 42 | (41) |
Total other (income) expense | (15,032) | (4,710) |
Net loss | (192,962) | (108,426) |
Net Income (Loss) | (192,962) | (108,426) |
Unrealized gain (loss) on marketable securities | 1,121 | (1,023) |
Foreign currency translation | (48) | (42) |
Comprehensive loss | $ (191,889) | $ (109,491) |
Net loss per share attributable to common shareholders, basic | $ (3.3) | $ (2.07) |
Net loss per share attributable to common shareholders, diluted | $ (3.3) | $ (2.07) |
Shares used to compute basic net loss per share attributable to common shareholders | 58,542,974 | 52,471,003 |
Shares used to compute diluted net loss per share attributable to common shareholders | 58,542,974 | 52,471,003 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 51,579 | $ 64,819 |
Marketable securities | 200,641 | 253,122 |
Prepaid expenses and other assets | 12,125 | 12,747 |
Total current assets: | 264,345 | 330,688 |
Property and equipment, net | 762 | 407 |
Operating lease right-of-use assets | 11,509 | 1,537 |
Marketable securities | 38,672 | |
Restricted cash | 975 | |
Other long-term assets | 102 | 96 |
Total assets | 277,693 | 371,400 |
Current liabilities | ||
Accounts payable | 5,756 | 6,433 |
Accrued expenses | 15,508 | 9,514 |
Current portion of operating lease liabilities | 1,001 | 412 |
Total current liabilities | 22,265 | 16,359 |
Operating lease liabilities, net of current portion | 11,505 | 1,146 |
Total liabilities | 33,770 | 17,505 |
Commitments and contingencies (Note 7) | ||
Stockholders' equity: | ||
Common stock, $0.0001 par value; 900,000,000 shares authorized at December 31, 2023 and December 31, 2022; 59,252,349 and 57,025,847 shares issued at December 31, 2023 and December 31, 2022, respectively; 59,239,113 and 56,980,845 shares outstanding at December 31, 2023 and December 31, 2022 respectively | 6 | 6 |
Additional paid-in capital | 663,154 | 581,237 |
Accumulated other comprehensive loss | (50) | (1,123) |
Accumulated deficit | (419,187) | (226,225) |
Total stockholders' equity | 243,923 | 353,895 |
Total liabilities and stockholders' equity | $ 277,693 | $ 371,400 |